International Journal of Hematology最新文献_第10页

COVID-19-induced thrombotic microangiopathy in patients with multiple myeloma receiving carfilzomib treatment. 接受卡非佐米治疗的多发性骨髓瘤患者covid -19诱导的血栓性微血管病变

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-05-05 DOI: 10.1007/s12185-025-03996-0

Kaito Takikawa, Mana Sota, Shiori Nakashima, Yui Imai, Hirofumi Nakano, Tomoyuki Uchida, Morihiro Inoue, Masao Hagihara, Akiko Torii

{"title":"COVID-19-induced thrombotic microangiopathy in patients with multiple myeloma receiving carfilzomib treatment.","authors":"Kaito Takikawa, Mana Sota, Shiori Nakashima, Yui Imai, Hirofumi Nakano, Tomoyuki Uchida, Morihiro Inoue, Masao Hagihara, Akiko Torii","doi":"10.1007/s12185-025-03996-0","DOIUrl":"https://doi.org/10.1007/s12185-025-03996-0","url":null,"abstract":"A 62-year-old woman experienced severe renal insufficiency and significant thrombocytopenia during the 7th cycle of carfilzomib and dexamethasone therapy for relapsed multiple myeloma. She was diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection from a routine check upon admission. She was subsequently diagnosed with thrombotic microangiopathy (TMA) as well, and platelet fragments were detected in her blood. Treatment with plasma exchange, hemodialysis, and antiviral medications was successful. Although coronavirus disease 2019 (COVID-19) was identified as the primary trigger of TMA, carfilzomib was probably a predisposing factor that contributed to endothelial damage. Even though severe cases of COVID-19 have been less frequent since the Omicron variant became dominant, patients with MM, especially those under treatment with carfilzomib, should be given repeated booster vaccinations. Antiviral medication should also be considered in patients infected with COVID-19, even if symptoms are mild.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

JSH practical guidelines for hematological malignancies, 2023: II. lymphoma-overview. 恶性血液病实用指南，2023:II。lymphoma-overview。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-05-01 Epub Date: 2025-03-04 DOI: 10.1007/s12185-025-03920-6

Ken Ohmachi

引用次数: 0

Real-world effectiveness of ixazomib, lenalidomide and dexamethasone in Asians with relapsed/refractory multiple myeloma. 伊唑唑米、来那度胺和地塞米松在亚洲复发/难治性多发性骨髓瘤患者中的实际疗效

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-05-01 Epub Date: 2025-03-20 DOI: 10.1007/s12185-025-03927-z

Soo Chin Ng, Joon-Ho Moon, Sung Soo Park, Youngil Koh, Ji Hyun Lee, Hyeon-Seok Eom, Ho-Jin Shin, Sung Hoon Jung, Young Rok Do, Gilbert Wilfred, Azlan Husin, Hyo Jung Kim, SFadilah Abdul Wahid, Myung-Won Lee, Hye-Won Heo, Kihyun Kim, Suporn Chuncharunee

{"title":"Real-world effectiveness of ixazomib, lenalidomide and dexamethasone in Asians with relapsed/refractory multiple myeloma.","authors":"Soo Chin Ng, Joon-Ho Moon, Sung Soo Park, Youngil Koh, Ji Hyun Lee, Hyeon-Seok Eom, Ho-Jin Shin, Sung Hoon Jung, Young Rok Do, Gilbert Wilfred, Azlan Husin, Hyo Jung Kim, SFadilah Abdul Wahid, Myung-Won Lee, Hye-Won Heo, Kihyun Kim, Suporn Chuncharunee","doi":"10.1007/s12185-025-03927-z","DOIUrl":"10.1007/s12185-025-03927-z","url":null,"abstract":"Randomized clinical trials have shown ixazomib, lenalidomide and dexamethasone (IRd) to be efficacious and safe in Asian patients with relapsed/refractory multiple myeloma (RRMM); however, real-world data are limited. The APEX study was a multicenter, observational cohort study of IRd conducted at 16 sites across South Korea, Malaysia, and Thailand. Overall, 104 patients treated with IRd during 2016-2023 were enrolled; data were collected by retrospective chart review and 6-month prospective follow-up. Median age at IRd initiation was 64.0 years. The primary endpoints of median time to next treatment (TTNT) and overall response rate (ORR) were 32.1 months and 72.1%, respectively (though ORR varied across countries). The secondary endpoint of median progression-free survival was 27.7 months, while median overall survival was not reached. Median TTNT and ORR were higher in elderly patients (≥65 and/or ≥70 years) than in the overall population. Adverse events occurred in 90.4% and serious adverse events occurred in 29.8% of all patients; common Grade ≥ 3 adverse drug reactions were pneumonia (9.6%), neutropenia (7.7%), and gastroenteritis (2.9%). This study demonstrated that IRd was safe and effective in real-world practice in Asia, including for elderly patients, and the results are aligned with TOURMALINE-MM1 and other real-world studies.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"670-683"},"PeriodicalIF":1.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12014722/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Primary pancreatic diffuse large B-cell lymphoma, appearing as an asymptomatic bulky mass with the duct-penetrating sign. 原发性胰腺弥漫性大b细胞淋巴瘤，表现为无症状的大块肿块，伴导管穿透征。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-05-01 Epub Date: 2025-03-06 DOI: 10.1007/s12185-025-03964-8

Naonori Harada

引用次数: 0

Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 3: solid cancers and vascular abnormalities. 日本2024弥散性血管内凝血管理临床实践指南第三部分：实体癌和血管异常。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-05-01 Epub Date: 2025-01-10 DOI: 10.1007/s12185-024-03912-y

Yoshinobu Seki, Kohji Okamoto, Takayuki Ikezoe, Kazuma Yamakawa, Seiji Madoiwa, Toshimasa Uchiyama, Hidesaku Asakura, Shinya Yamada, Shin Koga, Hiroyasu Ishikura, Takashi Ito, Toshiaki Iba, Mitsuhiro Uchiba, Kaoru Kawasaki, Noriaki Kawano, Satoshi Gando, Shigeki Kushimoto, Yuichiro Sakamoto, Toshihisa Tamura, Kenji Nishio, Mineji Hayakawa, Takeshi Matsumoto, Toshihiko Mayumi, Hideo Wada

{"title":"Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 3: solid cancers and vascular abnormalities.","authors":"Yoshinobu Seki, Kohji Okamoto, Takayuki Ikezoe, Kazuma Yamakawa, Seiji Madoiwa, Toshimasa Uchiyama, Hidesaku Asakura, Shinya Yamada, Shin Koga, Hiroyasu Ishikura, Takashi Ito, Toshiaki Iba, Mitsuhiro Uchiba, Kaoru Kawasaki, Noriaki Kawano, Satoshi Gando, Shigeki Kushimoto, Yuichiro Sakamoto, Toshihisa Tamura, Kenji Nishio, Mineji Hayakawa, Takeshi Matsumoto, Toshihiko Mayumi, Hideo Wada","doi":"10.1007/s12185-024-03912-y","DOIUrl":"10.1007/s12185-024-03912-y","url":null,"abstract":"This study discusses disseminated intravascular coagulation (DIC) associated with solid cancers and various vascular abnormalities, both of which generally exhibit chronic DIC patterns. Solid cancers are among the most significant underlying diseases that induce DIC. However, the severity, bleeding tendency, and progression of DIC vary considerably depending on the type and stage of the cancer, making generalization difficult. Moreover, during the process of creating these guidelines, it became apparent that despite solid cancers being a major underlying condition for DIC, there is a lack of high-quality research on DIC associated with solid cancers. Nevertheless, we developed recommendations for clinical questions (CQs) regarding the use of heparin and recombinant thrombomodulin. Additionally, statements concerning these five questions were provided. DIC associated with various vascular abnormalities, is characterized by hyperfibrinolytic activity and linked to underlying conditions such as aortic aneurysm, aortic dissection, vasculitis syndromes, and vascular malformations. These conditions must always be considered differential diagnoses when unexplained thrombocytopenia or bleeding tendencies are observed. Although no evidence was found to support the assignment of recommendation levels, three statements were made. However, traumatic vascular abnormalities have not been discussed in this context.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"622-632"},"PeriodicalIF":1.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142948610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 1: sepsis. 2024 年日本弥散性血管内凝血管理临床实践指南。第 1 部分：败血症。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-05-01 Epub Date: 2024-12-16 DOI: 10.1007/s12185-024-03896-9

Kazuma Yamakawa, Kohji Okamoto, Yoshinobu Seki, Takayuki Ikezoe, Takashi Ito, Toshiaki Iba, Satoshi Gando, Noritaka Ushio, Takaaki Totoki, Takeshi Wada, Hidesaku Asakura, Hiroyasu Ishikura, Mitsuhiro Uchiba, Toshimasa Uchiyama, Kaoru Kawasaki, Noriaki Kawano, Shigeki Kushimoto, Shin Koga, Yuichiro Sakamoto, Toshihisa Tamura, Kenji Nishio, Mineji Hayakawa, Takeshi Matsumoto, Seiji Madoiwa, Toshihiko Mayumi, Shinya Yamada, Hideo Wada

{"title":"Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 1: sepsis.","authors":"Kazuma Yamakawa, Kohji Okamoto, Yoshinobu Seki, Takayuki Ikezoe, Takashi Ito, Toshiaki Iba, Satoshi Gando, Noritaka Ushio, Takaaki Totoki, Takeshi Wada, Hidesaku Asakura, Hiroyasu Ishikura, Mitsuhiro Uchiba, Toshimasa Uchiyama, Kaoru Kawasaki, Noriaki Kawano, Shigeki Kushimoto, Shin Koga, Yuichiro Sakamoto, Toshihisa Tamura, Kenji Nishio, Mineji Hayakawa, Takeshi Matsumoto, Seiji Madoiwa, Toshihiko Mayumi, Shinya Yamada, Hideo Wada","doi":"10.1007/s12185-024-03896-9","DOIUrl":"10.1007/s12185-024-03896-9","url":null,"abstract":"The Japanese Society on Thrombosis and Hemostasis (JSTH) published the first-ever disseminated intravascular coagulation (DIC) guidelines in 2009. Fifteen years later, the JSTH developed new guidelines covering DIC associated with various underlying conditions. These guidelines were developed in accordance with the GRADE system to determine the strength of the recommendations and certainty of the evidence. This article was drafted as Part 1 of an overall DIC guideline covering various underlying conditions, with sepsis as the subject. In this section, seven key clinical issues (questions) are set. Question 1, regarding DIC diagnosis, introduces several diagnostic criteria, such as the JAAM-2, ISTH overt, SIC, and JSTH DIC criteria and recommends choosing the appropriate diagnostic criteria for DIC based on an understanding of their diagnostic properties. For pharmacotherapy in DIC patients with sepsis, we recommend the administration of antithrombin (Question 2) and recombinant thrombomodulin (Question 3) (both GRADE 1B). However, we do not make a clear recommendation regarding the administration of heparin (Question 6) and serine protease inhibitors (Question 7) because of the lack of evidence. Combination therapy, order of administration, and other administration methods for antithrombin and recombinant thrombomodulin are proposed as important future research questions (Questions 4 and 5).","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"592-604"},"PeriodicalIF":1.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142828352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk of ankylosing spondylitis in long-term follow-up of hematopoietic stem cell donors: impact of HLA-B27 status and donation type. 造血干细胞供者长期随访中强直性脊柱炎的风险：HLA-B27状态和供体类型的影响

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-05-01 Epub Date: 2025-02-27 DOI: 10.1007/s12185-025-03926-0

Sung-Chao Chu, Chia-Jung Hsieh, Shang-Hsien Yang, Kuo-Liang Yang, Kuei-Ying Su, Wei-Han Huang, Dian-Kun Li, Woei-Yau Kao, Szu-Chin Li, Sheng-Chuan Huang, Chi-Cheng Li, Ruey-Ho Kao, Tso-Fu Wang

{"title":"Risk of ankylosing spondylitis in long-term follow-up of hematopoietic stem cell donors: impact of HLA-B27 status and donation type.","authors":"Sung-Chao Chu, Chia-Jung Hsieh, Shang-Hsien Yang, Kuo-Liang Yang, Kuei-Ying Su, Wei-Han Huang, Dian-Kun Li, Woei-Yau Kao, Szu-Chin Li, Sheng-Chuan Huang, Chi-Cheng Li, Ruey-Ho Kao, Tso-Fu Wang","doi":"10.1007/s12185-025-03926-0","DOIUrl":"10.1007/s12185-025-03926-0","url":null,"abstract":"Hematopoietic stem cell transplantation (HSCT) is a pivotal curative therapy for various hematologic diseases, and donor safety is paramount. A few cases of ankylosing spondylitis (AS) have been reported in healthy unrelated donors, but the incidence has not been previously described. This retrospective cohort study analyzed 1098 bone marrow (BM) and 3890 peripheral blood stem cell (PBSC) donors between January 1998 and December 2018, along with healthy participants from the donor registry using de-identified data from the Taiwan National Health Insurance Research Database. The overall AS incidences among donors and non-donors were both 0.38%. AS incidence did not differ between BM and PBSC donors and their matched counterparts. Individuals with HLA-B27 exhibited higher incidence rate ratios than those without HLA-B27 in both the BM and PBSC cohorts. In those individuals with HLA-B27, BM donors showed a relative risk of 3.85 (p = 0.0017) compared to non-donors, while the risk for PBSC donors was not significantly higher (1.36, p = 0.339). The findings suggest that while AS incidence among HSC donors is comparable to non-donors, HLA-B27 positivity is the main risk factor associated with AS development, particularly among BM donors. This study provides valuable insights into the safety of HSCT donation and long-term follow-up.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"684-693"},"PeriodicalIF":1.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chronic graft-versus-host disease myelitis successfully treated with rituximab. 利妥昔单抗成功治疗慢性移植物抗宿主病脊髓炎。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-05-01 Epub Date: 2025-01-31 DOI: 10.1007/s12185-025-03936-y

Emi Yokoyama, Yuta Hasegawa, Kentaro Wakaki, Touma Suzuki, Sayaka Kajikawa, Minoru Kanaya, Koh Izumiyama, Makoto Saito, Masanobu Morioka, Jun Nagai, Tomoe Ichiki, Ryo Kikuchi, Satomi Okada, Hiroyuki Ohigashi, Hideki Goto, Masahiro Onozawa, Daigo Hashimoto, Akio Mori, Takanori Teshima, Takeshi Kondo

{"title":"Chronic graft-versus-host disease myelitis successfully treated with rituximab.","authors":"Emi Yokoyama, Yuta Hasegawa, Kentaro Wakaki, Touma Suzuki, Sayaka Kajikawa, Minoru Kanaya, Koh Izumiyama, Makoto Saito, Masanobu Morioka, Jun Nagai, Tomoe Ichiki, Ryo Kikuchi, Satomi Okada, Hiroyuki Ohigashi, Hideki Goto, Masahiro Onozawa, Daigo Hashimoto, Akio Mori, Takanori Teshima, Takeshi Kondo","doi":"10.1007/s12185-025-03936-y","DOIUrl":"10.1007/s12185-025-03936-y","url":null,"abstract":"Chronic graft-versus-host disease (cGVHD) is a major serious complication after allogeneic stem-cell transplantation (allo-HSCT), and often mimics autoimmune diseases. Central nervous system (CNS) symptoms are rare manifestations of cGVHD, and are difficult to diagnose. CNS manifestations of cGVHD were discussed in the 2020 National Institutes of Health cGVHD Consensus Project as one of the \"atypical cGVHD manifestations\" with involvement of various organ systems other than classical cGVHD organs. We experienced a case of myelitis after allo-HSCT diagnosed as cGVHD of the CNS. The neurological symptoms progressed after corticosteroid pulse therapy, resulting in severe paralysis and paresthesia of the lower extremities. The clinical course and magnetic resonance imaging findings showed some similarities with multiple sclerosis. We decided to use rituximab after the patient became refractory to corticosteroids because rituximab has been reported to be effective in multiple sclerosis by suppressing B cells on both sides of the blood-brain barrier. Rituximab was effective for the neurologic symptoms in our case. In atypical cGVHD, treatments used in corresponding autoimmune diseases may be reasonable and effective.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"712-717"},"PeriodicalIF":1.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12014695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143065523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024: significance of guidelines developed for each underlying disease. 日本2024弥散性血管内凝血管理临床实践指南：针对每种潜在疾病制定指南的意义

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-05-01 Epub Date: 2025-02-15 DOI: 10.1007/s12185-025-03928-y

Hidesaku Asakura

{"title":"Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024: significance of guidelines developed for each underlying disease.","authors":"Hidesaku Asakura","doi":"10.1007/s12185-025-03928-y","DOIUrl":"10.1007/s12185-025-03928-y","url":null,"abstract":"Disseminated intravascular coagulation (DIC) is a severe condition characterized by systemic, persistent activation of coagulation in the presence of an underlying disease, leading to the formation of microthrombi in small blood vessels. In DIC, fibrinolysis is also activated alongside coagulation, but the extent of fibrinolysis varies significantly depending on the underlying condition. The classification of DIC types is crucial not only for understanding the pathophysiology involved, but also for selecting appropriate treatment strategies. Internationally, DIC is often associated with sepsis, typically presenting with ischemic organ damage. However, it is important to recognize that some forms of DIC exhibit minimal ischemic organ damage but severe bleeding symptoms. When diagnosing and treating DIC, considering the underlying condition and disease type can lead to better clinical outcomes. This underscores the need for DIC management guidelines that are based on an understanding of the underlying disease. The newly released \"Clinical Practice Guidelines for Management of Disseminated Intravascular Coagulation in Japan 2024\" offer the first comprehensive guidelines for detailed management based on specific underlying conditions, providing a groundbreaking contribution to the global DIC clinical community.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"586-591"},"PeriodicalIF":1.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024: part 4-trauma, burn, obstetrics, acute pancreatitis/liver failure, and others. 日本2024弥散性血管内凝血管理临床实践指南：第4部分：创伤、烧伤、产科、急性胰腺炎/肝衰竭等。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2025-05-01 Epub Date: 2025-01-31 DOI: 10.1007/s12185-025-03918-0

Mineji Hayakawa, Yoshinobu Seki, Takayuki Ikezoe, Kazuma Yamakawa, Kohji Okamoto, Shigeki Kushimoto, Yuichiro Sakamoto, Yuki Itagaki, Yuki Takahashi, Hiroyasu Ishikura, Toshihiko Mayumi, Toshihisa Tamura, Kenji Nishio, Yu Kawazoe, Ayami Shigeno, Yudai Takatani, Akihito Tampo, Yoshihiko Nakamura, Katsunori Mochizuki, Noritaka Yada, Kaoru Kawasaki, Akira Kiyokawa, Mamoru Morikawa, Mitsuhiro Uchiba, Takeshi Matsumoto, Hidesaku Asakura, Seiji Madoiwa, Toshimasa Uchiyama, Shinya Yamada, Shin Koga, Takashi Ito, Toshiaki Iba, Noriaki Kawano, Satoshi Gando, Hideo Wada

{"title":"Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024: part 4-trauma, burn, obstetrics, acute pancreatitis/liver failure, and others.","authors":"Mineji Hayakawa, Yoshinobu Seki, Takayuki Ikezoe, Kazuma Yamakawa, Kohji Okamoto, Shigeki Kushimoto, Yuichiro Sakamoto, Yuki Itagaki, Yuki Takahashi, Hiroyasu Ishikura, Toshihiko Mayumi, Toshihisa Tamura, Kenji Nishio, Yu Kawazoe, Ayami Shigeno, Yudai Takatani, Akihito Tampo, Yoshihiko Nakamura, Katsunori Mochizuki, Noritaka Yada, Kaoru Kawasaki, Akira Kiyokawa, Mamoru Morikawa, Mitsuhiro Uchiba, Takeshi Matsumoto, Hidesaku Asakura, Seiji Madoiwa, Toshimasa Uchiyama, Shinya Yamada, Shin Koga, Takashi Ito, Toshiaki Iba, Noriaki Kawano, Satoshi Gando, Hideo Wada","doi":"10.1007/s12185-025-03918-0","DOIUrl":"10.1007/s12185-025-03918-0","url":null,"abstract":"Disseminated intravascular coagulation (DIC) is a complex condition with diverse etiologies. While its association with sepsis has been widely studied, less focus has been given to DIC arising from other critical conditions, such as trauma, burns, acute pancreatitis, and obstetric complications. The 2024 Clinical Practice Guidelines, developed by the Japanese Society on Thrombosis and Hemostasis (JSTH), aim to fill this gap and offer comprehensive recommendations for managing DIC across various conditions. This study, Part 4 of the guideline series, addresses DIC management in trauma, burns, obstetric complications, acute pancreatitis/liver failure, viral infections, and autoimmune diseases. For trauma-associated DIC, early administration of fresh-frozen plasma (FFP), coagulation factor concentrates such as fibrinogen and prothrombin complex concentrates, and tranexamic acid is recommended. The guidelines also highlight DIC in obstetrics, which is associated with massive bleeding, and recommend the administration of fibrinogen concentrate, antithrombin concentrate, and tranexamic acid. Through a systematic review of the current evidence, the guidelines provide stratified recommendations aimed at improving clinical outcomes in DIC management beyond sepsis, thereby serving as a valuable resource for healthcare providers globally.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"633-652"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143074320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0